PT - JOURNAL ARTICLE AU - Liu, Caigang AU - Yu, Hong AU - Chen, Guanglei AU - Yang, Qichao AU - Niu, Nan AU - Han, Ling AU - Zhao, Dongyu AU - Wang, Manji AU - Liu, Yuanyuan AU - Yang, Yongliang TI - An herbal drug combination identified by knowledge graph alleviates the clinical symptoms of plasma cell mastitis patients: a nonrandomized controlled trial AID - 10.1101/2022.12.01.22282958 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.01.22282958 4099 - http://medrxiv.org/content/early/2022/12/06/2022.12.01.22282958.short 4100 - http://medrxiv.org/content/early/2022/12/06/2022.12.01.22282958.full AB - Background Plasma cell mastitis (PCM) is a nonbacterial breast inflammation with severe and intense clinical manifestation yet treatment methods for PCM are still rather limited. Although the mechanism of PCM remains unclear, mounting evidences suggest that the dysregulation of immune system is closely associated with the pathogenesis of PCM. Drug combinations or combination therapy could exert improved efficacy and reduced toxicity through hitting multiple discrete cellular targets.Methods We have developed a knowledge graph architecture towards immunotherapy and systematic immunity that consists of herbal drug-target interactions with a novel scoring system to select drug combinations based on target-hitting rates and phenotype relativeness. To this end, we employed this knowledge graph to identify an herbal drug combination for PCM and we subsequently evaluated the efficacy of the herbal drug combination in clinical trialResults Our clinical data suggests that the herbal drug combination could significantly reduce the serum level of various inflammatory cytokines, downregulate serum IgA and IgG level, reduce the recurrence rate and reverse the clinical symptoms of PCM patients with improvements of general health status.Conclusions In summary, we reported that an herbal drug combination identified by knowledge graph can alleviate the clinical symptoms of plasma cell mastitis patients. We demonstrated that the herbal drug combination holds great promise as an effective remedy for PCM, acting through the regulation of immunoinflammatory pathways and improvement of systematic immune level. In particular, the herbal drug combination could significantly reduce the recurrence rate of PCM, a major obstacle for PCM treatment. Our data suggests that the herbal drug combination is expected to feature prominently in future PCM treatment.Funding C. Liu’s lab was supported by grants from the Public Health Science and Technology Project of Shenyang (Grant: 22-321-32-18); Y. Yang’s laboratory was supported by the National Natural Science Foundation of China (Grant: 81874301), the Fundamental Research Funds for Central University (Grant: DUT22YG122) and the Key Research project of ‘be Recruited and be in Command’ in Liaoning Province (Personal Target Discovery for Metabolic Diseases).Clinical trial number ClinicalTrials.gov: NCT05530226Competing Interest StatementLing Han is an employee of China Resources Sanjiu Medical & Pharmaceutical; Manji Wang is an employee of Shanghai BeautMed Corporation.Clinical TrialThis study was registered with ClinicalTrials.gov: NCT05530226.Funding StatementY. Yang's laboratory was supported by the National Natural Science Foundation of China (Grant: 81874301), the Fundamental Research Funds for Central University (Grant: DUT22YG122) and the Key Research project of 'be Recruited and be in Command' in Liaoning Province (Personal Target Discovery for Metabolic Diseases); C. Liu's lab was supported by grants from the National Natural Science Foundation of China (No. 81572609), China Medical University Major Construction Project (No. 2017ZDZX05) and Liaoning Colleges Innovative Talent Support Program (Cancer Stem Cell Origin and Biological Behavior).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Institutional Review Board (IRB) of the China Medical University (approval number: 2021PS024T). This study was registered with ClinicalTrials.gov: NCT05530226. All patients provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data refereed to in the manuscript are available to the public.